FOSTER CITY, Calif. & WILMINGTON, Del., September 25, 2026--Mirum and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Pro
The Food and Drug Administration’s target date is Saturday, September 26, for zilurgisertib, a once-daily pill for fibrodysplasia ossificans progressiva, or FOP, in patients 12 and older.
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-third-treatment-fibrodysplasia-ossificans-progressiva
Incyte has delivered a strong multi year share-price run, so the obvious follow up is whether the current valuation is still grounded in the cash the business is expected to generate. With investors w
Incyte (NasdaqGS: INCY) plans to present new clinical data on its inflammation and autoimmunity portfolio at the upcoming EADV Congress. The presentation will spotlight updates for Opzelura, ruxolitin
Morgan Stanley highlights high-risk, high-reward biotech stocks poised for massive upside following key upcoming clinical readouts.
Incyte is gaining momentum, recently outperforming the biotech sector and keeping analysts broadly positive on the stock.
Dow Jones tech titan Amazon stock is battling with a key support level and approaching multiple new buy points.
View interactive chart, options flow, and AI analysis for INCY on Zorveq Finance.
Open INCY Chart & Analysis →